Cariprazine Publications 2006-2023

Clinical

Schizophrenia

The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post-hoc analysis of 3 randomised, placebo-controlled trials Open access
Falkai P, Dombi ZB, Acsai K, Barabássy Á, Schmitt A, Németh G
CNS Spectrum. 2023; 28(1): 104-111. doi.org/10.1017/S1092852921000997

What is the minimum clinically important change in negative symptoms of schizophrenia? PANSS based post hoc analyses of a phase III clinical trial Open access
Czobor P, Sebe B, Acsai K, Barabassy A, Laszlovszky I, Németh G, Furukawa TA, Leucht S
Front Psychiatry. 2022; 13: 816339. doi.org/10.3389/fpsyt.2022.816339

Dosing cariprazine within and beyond clinical trials – recommendations for the treatment of schizophrenia Open access
Rancans E, Dombi ZB, Barabassy A
Front Psychiatry. 2022; 12: 770234. doi.org/10.3389/fpsyt.2021.770234

Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases. Letter to the Editor Open access
Németh G, Dombi ZB, Laszlovszky I, Barabássy Á
Expert Opin Pharmacother. 2022; 23(12): 1467-1468. doi.org/10.1080/14656566.2021.1968827

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms Open access
Demyttenaere K, Leenaerts N, Acsai K, Sebe B, Laszlovszky I, Barabássy Á, Fonticoli L, Szatmári B, Earley W, Németh G, Correll CU
Eur Psychiatry, 2022; 65(1): e18. doi.org/10.1192/j.eurpsy.2021.2241

Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety Open access
Laszlovszky I, Barabássy Á, Németh G
Adv Ther. 2021; 38(7): 3652-3673. doi.org/10.1007/s12325-021-01797-5

The burden of caring for someone with schizophrenia: A cross country report from Bulgaria, the Czech Republic, Hungary and Russia
Sebe B, Barabássy Á, Buksa K, Laszlovszky I, Dombi ZB, Németh G, Falkai P
Psychiatria Hungarica. 2021; 36(4): 564-556. PubMed PMID: 34939572

The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: An observational study Open access
Rancans E, Dombi ZB, Mátrai P, Barabássy Á, Sebe B, Skrivele I, Németh G
Int Clin Psychopharmacol. 2021; 36(3): 154-161. doi.org/10.1097/YIC.0000000000000351

Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies Open access
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G
Neuropsychiatr Dis Treat. 2021; 17: 957-970. doi.org/10.2147/NDT.S301225
Corrigendum: Neuropsychiatr Dis Treat. 2021; 17: 1481. doi.org/10.2147/NDT.S316858

Cariprazine safety in adolescents and the elderly: Analyses of clinical study data Open access
Szatmári B, Barabássy Á, Harsányi J, Laszlovszky I, Sebe B, Gál M, Shiragami K, Németh G
Front Psychiatry. 2020; 11: 61. doi.org/10.3389/fpsyt.2020.00061

Cariprazine therapy in the spirit of functionality – new ways in schizophrenia treatment (Published in Hungarian with English abstract)
Laszlovszky I, Barabássy Á, Németh G
Psychiat Hung. 2020; 35(Suppl 1): 12-26.

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies Open access
Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S
Eur Neuropsychopharmacol. 2019; 29(1): 127-136. doi.org/10.1016/j.euroneuro.2018.10.008

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data Open access
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, Patel M, Barabássy A, Szatmári B, Németh G
Schizophr Res. 2019; 204: 282-288. doi.org/10.1016/j.schres.2018.08.020

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors Open access
Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G
Eur Psychiatry. 2019; 58: 1-9. doi.org/10.1016/j.eurpsy.2019.01.015

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia Open access
Leucht S, Barabássy A, Laszlovszky I, Szatmári B, Acsai K, Szalai E, Harsányi J, Earley W, Németh G
Neuropsychopharmacology. 2019; 44(9): 1589-1596. doi.org/10.1038/s41386-019-0363-2

Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial Open access
Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W
J Clin Psychiatry. 2019; 80(2): 18m12495. doi.org/10.4088/JCP.18m12495

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation Open access
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W
Neuropsychiatr Dis Treat. 2019; 15: 2537–2550. doi.org/10.2147/NDT.S210340

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study Open access
Cutler A, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G
CNS Spectrum. 2018; 23(1): 39-50. doi.org/10.1017/S1092852917000220

Negative symptoms of schizophrenia: Constructs, burden, and management Open access
Barabássy A, Szatmári B, Laszlovszky I, Németh G
Psychotic Disorders: An Update; Edited by Federico Durbano, IntechOpen, 2018, pp. 43-62. ISBN 978-953-51-5976-6; doi.org/10.5772/intechopen.73300

Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial Open access at Richter website
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW
Lancet. 2017; 389(10074): 1103-1113. doi.org/10.1016/S0140-6736(17)30060-0

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis Open access
Nasrallah H, Earley W, Cutler A, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S
BMC Psychiatry. 2017; 17(1): 305. doi.org/10.1186/s12888-017-1459-z

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study Open access
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S
Psychopharmacology. 2017; 234(2): 199-209. doi.org/10.1007/s00213-016-4450-3

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies Open access
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM
Int Clin Psychopharmacol. 2017; 32(6): 319-328. doi.org/10.1097/YIC.0000000000000187

Cariprazine in the treatment of schizophrenia: A proof-of-concept trial Open access
Durgam S, Litman R, Papadakis K, Li D, Németh G, Laszlovszky I
Int Clin Psychopharmacol. 2016; 31(2): 61-68. doi.org/10.1097/YIC.0000000000000110

The effect of cariprazine on hostility associated with schizophrenia Open access
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I
J Clin Psychiatry . 2016; 77(1): 109-115. doi.org/10.4088/JCP.15m10192

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial Open access
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA
Schizophr Res. 2016; 176(2-3):264-271. doi.org/10.1016/j.schres.2016.06.030

Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial Open access
Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY
J Clin Psychiatry. 2015; 76(12):e1574-1582. doi.org/10.4088/JCP.15m09997

Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial Open access
Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S
J Clin Psychopharmacol. 2015; 35(4): 367-373. doi.org/10.1097/JCP.0000000000000346

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial Open access
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I
Schizophr Res. 2014; 152(2-3): 450-457. doi.org/10.1016/j.schres.2013.11.041

Bipolar Disorder (Bipolar Mania, Bipolar Depression)

Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System Open access
Heinz Grunze, Réka Csehi, Christoph Born and Ágota Barabássy
Front Psychiatry. 2021; 12: 803208. doi.org/10.3389/fpsyt.2021.803208

Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression Open access
Citrome L, Yatham LN, Patel MD, Barabássy Á, Hankinson A, Earley WR
J Affect Disord. 2021; 288: 191-198. doi.org/10.1016/j.jad.2021.03.076

Efficacy of cariprazine in bipolar I depression across patient characteristics: A post hoc analysis of pooled randomized, placebo-controlled studies Open access
Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN
Int Clin Psychopharmacol. 2021; 36(2): 76-83. doi.org/10.1097/YIC.0000000000000344

The efficacy of cariprazine on function in patients with bipolar depression: A post hoc analysis of a randomized controlled trial Open access
Vieta E, Calabrese JR, Whelan J, Tohen M, Earley WR
Curr Med Res Opin. 2021; 37(9): 1635-1643. doi.org/10.1080/03007995.2021.1932446

Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications Open access
Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W
Prim Care Companion CNS Disord. 2020; 22(5): 20m02611. doi.org/10.4088/PCC.20m02611

Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies Open access
McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM
CNS Spectrum. 2020; 25(4): 502-510. doi.org/10.1017/S1092852919001287

Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study Open access
Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR
Bipolar Disord. 2020; 22: 372-384. doi.org/ 10.1111/bdi.12852

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial Open access
Yatham LN, Vieta E, Earley WR
Int Clin Psychopharmacol. 2020; 35: 147-156. doi.org/10.1097/YIC.0000000000000307

A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression Open access
Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN
J Affec Disord. 2020; 263: 386-395. doi.org/10.1016/j.jad.2019.11.098

Cariprazine treatment of bipolar depression: A randomized, double blind, placebo-controlled phase 3 study Open access
Earley W, Burgess M, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN
Am J Psychiatry. 2019; 176(6): 439-448. doi.org/10.1176/appi.ajp.2018.18070824

Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials Open access
McIntyre RS, Masand PS, Earley W, Patel M
J Affect Disord. 2019; 257: 600-606. doi.org/10.1016/j.jad.2019.07.020

Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder Open access
Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, Yatham LN
J Affect Disord. 2018; 226: 239-244. doi.org/10.1016/j.jad.2017.09.040

The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study Open access
Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G
J Affect Disord. 2018; 225: 350-356. doi.org/10.1016/j.jad.2017.08.040

Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies Open access
Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN
J Affect Disord. 2017; 215: 205-212. doi.org/10.1016/j.jad.2017.03.032

An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression Open access
Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, Vieta E, Calabrese JR, Yatham LN
Am J Psychiatry. 2016; 173(3): 271-281. doi.org/10.1176/appi.ajp.2015.15020164

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial Open access
Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S
J Affect Disord. 2015; 174: 296-302. doi.org/10.1016/j.jad.2014.11.018

Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder Open access
Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S
J Clin Psychiatry. 2015; 76(3): 284-292. doi.org/10.4088/JCP.14m09081

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial Open access
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I
Bipolar Disord. 2015; 17(1): 63-75. doi.org/10.1111/bdi.12238

Major Depression

Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Gary S. Sachs, Paul P. Yeung, Ludmyla Rekeda, Arifulla Khan, Julie L. Adams, Maurizio Fava
Am J Psychiatry, 2023; 180(3): 241-251. doi.org/10.1176/appi.ajp.20220504

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder Open access
Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G
Int Clin Psychopharmacol. 2019; 34(2): 76-83. doi.org/10.1097/YIC.0000000000000246

Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial Open access
Earley W, Guo H, Németh G, Harsányi J, Thase M
Psychopharmacology Bull. 2018; 48(4): 62-80.

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial Open access
Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G
Int Clin Psychopharmacol. 2018; 33(6): 312-321. doi.org/10.1097/YIC.0000000000000235

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients Open access
Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA
J Clin Psychiatry. 2016; 77(3): 371-378. doi.org/10.4088/JCP.15m10070

All Indications

Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia
Riccobene T, Riesenberg R, Yeung PP, Earley WR, Hankinson AL
J Child Adolesc Psychopharmacol. 2022; 32(8): 434-443. doi.org/10.1089/cap.2021.0139

Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists. Editorial Open access
Németh G, Csehi R
Front Psychiatry 2022; 13: 1038627. doi.org/10.3389/fpsyt.2022.1038627

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
Open access
Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR
Neuropsychiatr Dis Treat. 2022; 18: 995-1011. doi.org/10.2147/NDT.S348143

Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies Open access
Csehi R, Dombi ZB, Sebe B, Molnár MJ
Front. Psychiatry. 2022; 13: 827744. doi.org/10.3389/fpsyt.2022.827744

The Efficacy of Cariprazine on Cognition: A Post Hoc Analysis From Phase II/III Clinical Trials in Bipolar Mania, Bipolar Depression, and Schizophrenia
McIntyre RS, Daniel DG, Vieta E, Laszlovszky I, Goetghebeur PJ, Earley W, Patel M
CNS Spectrum. 2023; 28(3): 319-330. doi.org/10.1017/S109285292200013X

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis Open access
Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE
Int J Clin Pract. 2017; 71(12): e13037. doi.org/10.1111/ijcp.13037

Other Indications

Improving mood and cognitive symptoms in Huntington's disease with cariprazine treatment
Open access
Molnar MJ, Molnar V, Fedor M, Csehi R, Acsai K, Borsos B, Grosz Z
Front Psychiatry. 2022; 12: 825532. doi.org/10.3389/fpsyt.2021.825532

Wernicke–Korsakoff syndrome associated with mtDNA disease Open access
Jimoh IJ, Sebe B, Balicza P, Fedor M, Pataky I, Rudas G, Gál A, Inczédy-Farkas G, Németh G, Molnár MJ
Ther Adv Neurol Disord. 2020; 13: 1756286420938972. doi.org/10.1177/1756286420938972

Non-clinical

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo Open access
Kiss B, Krámos B, Laszlovszky I
Front. Psychiatry. 2022; 13: 785592. doi.org/10.3389/fpsyt.2022.785592

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders Open access
Kehr J, Wang FH, Ichinose F, Yoshitake S, Farkas B, Kiss B, Adham N
Front. Psychiatry. 2022; 12: 801641. doi.org/10.3389/fpsyt.2021.801641

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of Autism Spectrum Disorder Open access
Román V, Adham N, Foley A, Hanratty L, Farkas B, Lendvai B, Kiss B
Psychopharmacol. 2021; 238(9): 2381-2392. doi.org/10.1007/s00213-021-05851-6

Cariprazine modulates sleep architecture in rats
Nyitrai G, Kiss B, Farkas B, Balázs O, Diószegi P, Lendvai B, Czurkó A
J Psychopharmacol. 2021; 35(3): 303-310. doi.org/10.1177/0269881120981378

C-N Bond Formation by Consecutive Continuous-Flow Reductions towards A Medicinally Relevant Piperazine Derivative Open access
Fülöp Z, Bana P, Greiner I, Éles J
Molecules. 2021; 26(7): 2040. doi.org/10.3390/molecules26072040

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
Open access
Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Bence Farkas, Béla Kiss and Nika Adham
Front. Psychiatry. 2022; 12: 801641. doi.org/10.3389/fpsyt.2021.801641

Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin$_{1A}$ receptor neurotransmission in the hippocampus
El Mansari M, Ebrahimzadeh M, Hamati R, Iro CM, Farkas B, Kiss B, Adham N, Blier P
J Psychopharmacol. 2020; 34(10): 1143-1154. doi.org/10.1177/0269881120936891

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices Open access
Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z
Br J Pharmacol. 2020; 177(7): 1622-1634. doi.org/10.1111/bph.14923

The role of dopamine D_3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens
Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY;
J Pharmacol Exp Ther. 2019; 371(2): 517-525. doi.org/10.1124/jpet.119.259879

The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task Open access
Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B
Psychopharmacology. 2018; 235(5): 1403-1414. doi.org/10.1007/s00213-018-4857-0

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity Open access
Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N
Psychopharmacology. 2018; 235(5): 1593–1607. doi.org/10.1007/s00213-018-4874-z

Involvement of 5-HT1A and 5-HT2A receptors but not α2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo Open access
Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P
Mol Pharmacol. 2018; 94(6): 1363-1370. doi.org/10.1124/mol.118.113290

The novel atypical antipsychotic cariprazine demonstrates dopamine D_2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity Open access
Delcourte S, Ashby CR, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N
CNS Neurosci Ther. 2018; 24(12): 1129-1139. doi.org/10.1111/cns.12867

Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model Open access
Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS
Int J Neuropsychopharmacol. 2017; 20(10): 788-796. doi.org/10.1093/ijnp/pyx038

Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine Open access
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrum. 2017; 22(6): 484-494. doi.org/10.1017/S1092852916000894

The chemistry that lead to cariprazine (published in Hungarian with English abstract) Open access
Domány Gy, Greiner I
Magyar Kémiai Folyóirat 2016; 122: 112-116.

Discovery of cariprazine (chemical aspects) (published in Hungarian) Open access
Domány Gy
Magyar Kémikusok Lapja 2016; 71: 261-262.

The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia
Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC
Eur Neuropsychopharmacol. 2016; 26(2): 208-224. doi.org/10.1016/j.euroneuro.2015.12.020

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology Open access
Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N
Eur Neuropsychopharmacol. 2016; 26(1): 3-14. doi.org/10.1016/j.euroneuro.2015.11.016

Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices
El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N
Psychiatry Res. 2015; 229(1-2): 370-373. doi.org/10.1016/j.psychres.2015.05.114

Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression
Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I
Behav Pharmacol. 2014; 25(5-6): 567-574. doi.org/10.1097/FBP.0000000000000070

Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions Open access
Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS
Pharmacol Res Perspect. 2014; 3(1): e00073. doi.org/10.1002/prp2.73

Long-term effects of cariprazine exposure on dopamine receptor subtypes
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrum. 2014; 19(3): 268-277. doi.org/10.1017/S1092852913000680

Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11C]-cariprazine: An in vivo positron emission tomography study in non-human primates
Tóth M, Varróné A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B
Synapse. 2013; 67(5): 258-264. doi.org/10.1002/syn.21631

Cariprazine, a dopamine D3-receptor-preferrin partial agonist, block phencyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.
Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C
Psychopharmacology. 2013; 226(1): 91-100. doi.org/10.1007/s00213-012-2896-5

Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z
Psychopharmacology, 2013; 226(2): 285-293. doi.org/10.1007/s00213-012-2906-7

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors
Ágai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt É, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, M. Kapás, Z. Szombathelyi
Bioorg Med Chem Lett. 2012; 22(10): 3437-3440. doi.org/ 10.1016/j.bmcl.2012.03.104

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites
Kiss B, Horti F, Bobok A
Synapse. 2011; 65: 467-478. doi.org/10.1002/syn.20867

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B
Psychopharmacology. 2011; 218(3): 579-587. doi.org/10.1007/s00213-011-2343-z

RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and pro-cognitive effects in rodents
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Ágai-Csongor É, Domány G, Tihanyi K, Szombathelyi Z
Neurochem Int. 2011; 59(6): 925-935. doi.org/10.1016/j.neuint.2011.07.002

Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile
Kiss B, Horváth A, Némethy Z, Schmidt É, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Ágai-Csongor É, Domány G, Tihanyi K, Adham N, Szombathelyi Z
J Pharmacol Exp Ther. 2010; 333(1): 328-340. doi.org/10.1124/jpet.109.160432

Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B
J Pharmaceut Biomed Anal. 2008; 48: 678-684. doi.org/10.1016/j.jpba.2008.06.021

Pharmacokinetic (non-human, human)

Population pharmacokinetics of cariprazine and its major metabolites Open access
Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T
Eur J Drug Metab Pharmacokin. 2021; 46(1): 53-69. doi.org/10.1007/s13318-020-00650-4

Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania Open access
Periclou A, Willavize S, Jaworowicz D, Passarell J, Carrothers T, Ghahramani P, Durgam S, Earley W, Kapás M, Khariton T
Clin Transl Sci. 2020; 13(2): 362-371. doi.org/10.1111/cts.12720

Comment on: "Clinical pharmacokinetics of atypical antipsychotics: An update" Open access
Periclou A, Riccobene T, Kapás M, Laszlovszky I
Clinical Pharmacokinet. 2019; 58: 1215-1216. doi.org/10.1007/s40262-019-00795-9

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine Open access
Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sághy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B
Drug Des Devel Ther. 2019; 13: 3229-3248. doi.org/10.2147/DDDT.S188760

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Open access
Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y
Drug Design Develop Ther. 2016; 10: 327-338. doi.org/10.2147/DDDT.S95100

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO Open access
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A
Psychopharmacology. 2016; 233: 3503-3512. doi.org/10.1007/s00213-016-4382-y

Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine
Pásztor Mészáros G, Ágai-Csongor É, Kapás M
J Pharm Biomed Anal. 2008; 48(2): 388-497. doi.org/10.1016/j.jpba.2007.12.016

Health Technology Assessment (HTA)

Place of care and costs associated with acute episodes and remission in schizophrenia
McIntyre RS, Higa S, Doan QV, Amari DT, Mercer D, Gillard P, Harrington A
J. Manag. Care Spec. Pharm. 2023; 29(5): 499-508. doi.org/10.18553/jmcp.2023.29.5.499

Place of care and costs associated with acute episodes and remission in bipolar I disorder
Open access
McIntyre RS, Higa S, Doan QV, Amari D, Oliveri D, Gillard P, Harrington A
J Med Econ. 2022; 25(1): 1110-1117. doi.org/10.1080/13696998.2022.2120264

Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine Open access
Vokó Z, Bitter I, Mersich B, Réthelyi J, Molnár A, Pitter JG, Götze Á, Horváth M, Kóczián K, Fonticoli L, Lelli F, Németh B
Cost Eff Resour Alloc. 2020; 18: 28. doi.org/10.1186/s12962-020-00224-w

Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
Németh B, Bendes R, Nagy B, Götze Á, Kóczián K, Horváth M, Deák I, Tóth B, Kaló Z
Health Policy Tech. 2019; 8: 84-91. doi.org/10.1016/j.hlpt.2019.01.004

Population-level QALY gain estimates with the use of cariprazine for patients with negative symptoms of schizophrenia in Hungary (Published in Hungarian with English abstract) Open access
Bendes R, Németh B, Pitter JG, Kóczián K, Götze Á, Kaló Z
LAM 2019; 29: 467-475. doi.org/10.33616/LAM.29.045

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone Open access at Richter website
Németh B, Molnár A, Akehurst R, Horváth M, Kóczián K, Németh G, Götze Á, Vokó Z
J Comp Eff Res. 2017; 6: 639-648. doi.org/10.2217/cer-2017-0024

General (in Hungarian)

Challenges and Drivers in the International Development Process of the First Hungarian Blockbuster Molecule (Published in Hungarian) Open access
Németh G, Gulácsi G
IME: Interdiszciplináris Magyar Egészségügy. 2023; 22(1): 45-53. doi.org/10.53020/IME-2023-106

Drugs acting on dopamine D3 receptors: Clinical studies and therapeutic profiles (Published in Hungarian with English abstract)
Laszlovszky I
Gyógyszerészet. 2021; 65: 579-588, Published online: 20 October 2021.

Cariprazine (Reagila®) – a new mechanism of action antipsychotic with unique therapeutic possibilities for the treatment of schizophrenia and other psychiatric dysfunctions (Published in Hungarian with English abstract)
Laszlovszky I, Kiss B, Domány G, Kapás M, Barabássy Á, Szatmári B, Szombathelyi Z, Németh G, Greiner I
Gyógyszerészet. 2020; 64(12): 707-713.

Dopamine D3 receptors and antipsychotics - Aspects of mechanism of action and pharmacological properties - part I. (Published in Hungarian with English abstract)
Kiss B, Laszlovszky I, Krámos B
Gyógyszerészet. 2020; 64(4): 197-208.

Dopamine D3 receptors and antipsychotics - Aspects of mechanism of action and pharmacological properties - part II. (Published in Hungarian with English abstract)
Kiss B, Laszlovszky I, Krámos B
Gyógyszerészet. 2020; 64(5): 259-267.

Cariprazine, a new type – dopamine D_3 receptor preferring – partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms (Published in Hungarian with English abstract) Open access
Laszlovszky I, Kiss B, Barabássy Á, Kapás M, Németh G
Neuropsychopharmacol Hung. 2019; 21(3): 103-118. PubMed PMID: 31537751

In nutshell about cariprazine (Published in Hungarian)
Laszlovszky I, Barabássy Á
Psychiatric and Neurology Times – Hungarian ed. 2018; (5): 26-28.

Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.
A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)
Laszlovszky I, Németh G
Gyógyszerészet. 2015; 59: 643-646.